The company has not filed an annual or quarterly report since its Q3 FY2020 10-Q, filed Nov 6, 2020. Its latest SEC filing is a SC 13G/A from Feb 16, 2021.
10-Q for Q3 FY2020, filed Nov 6, 2020
The sections below describe the company as of the FY2019 annual report.
Sold Feraheme, an intravenous iron treatment for iron-deficiency anemia, to healthcare providers; also sold medicines for preterm birth and women’s health.
10-K for FY2019, filed Mar 6, 2020AMAG Pharmaceuticals, Inc., a Delaware corporation, was founded in 1981. We are a pharmaceutical company focused on bringing innovative…View ↗
Products and Product Candidates Uses and Potential Uses Regulatory Status Nature of Rights Feraheme®(ferumoxytol injection) IV iron…View ↗
Feraheme received approval from the U.S. Food and Drug Administration (the “FDA”) in June 2009 for use as an IV iron replacement therapy…View ↗
We sell Feraheme to authorized wholesalers and specialty distributors who, in turn, sell Feraheme to healthcare providers who administer…View ↗
Wholesalers and specialty distributors or pharmacies bought products directly and resold them to healthcare providers and patients; hospitals, government agencies and integrated delivery networks also bought Makena directly.
10-K for FY2019, filed Mar 6, 2020We principally sell our products to wholesalers, specialty distributors, specialty pharmacies and other customers (collectively…View ↗
We acquired the rights to Makena in connection with our acquisition of Lumara Health Inc. (“Lumara Health”) in November 2014. Makena is…View ↗
Makena prescriptions are dispensed via the payer-preferred pharmacy networks or purchased directly by hospitals, government agencies and…View ↗
10-Q for Q3 FY2020, filed Nov 7, 2020
$9.7MView ↗
8-K, filed Nov 17, 2020
In connection with the closing of the Merger, AMAG and Wilmington Trust, National Association, as trustee (the “Trustee”) entered into a…View ↗
8-K, filed Oct 6, 2020
On October 5, 2020, we received from the Center for Drug Evaluation and Research (“CDER”) of the Food and Drug Administration (“FDA”) a…View ↗
8-K, filed Aug 6, 2020
On August 6, 2020, the Company announced that Brian Piekos was appointed AMAG’s Executive Vice President and Chief Financial Officer…View ↗
8-K, filed Jul 23, 2020
AMAG will oversee a Phase 3 clinical program (the “Phase 3 Program”) to support regulatory approval of the Product by the U.S. Food and…View ↗
Cord blood services
The older report included CBR’s cord-blood collection, processing and storage services; the latest said AMAG had sold CBR and treated it as a discontinued business.
10-K for FY2016, filed Feb 21, 2017 10-K for FY2019, filed Mar 6, 2020AMAG Pharmaceuticals, Inc., a Delaware corporation, was founded in 1981. We are a biopharmaceutical company focused on developing and…View ↗
We intend to continue to expand the impact of our current and future products for patients by delivering on our growth strategy, which…View ↗
Broader Feraheme use
The older report described Feraheme for iron-deficiency anemia in adults with chronic kidney disease; the latest also included adults who could not tolerate oral iron or had an unsatisfactory response.
10-K for FY2016, filed Feb 21, 2017 10-K for FY2019, filed Mar 6, 2020Feraheme was approved for marketing by the FDA in June 2009 for use as an IV iron replacement therapy for the treatment of IDA in adult…View ↗
Feraheme received approval from the U.S. Food and Drug Administration (the “FDA”) in June 2009 for use as an IV iron replacement therapy…View ↗
Women’s health products
The older report described Rekynda as under development and Intrarosa as newly licensed; the latest described Vyleesi and Intrarosa as marketed medicines.
10-K for FY2016, filed Feb 21, 2017 10-K for FY2019, filed Mar 6, 2020AMAG Pharmaceuticals, Inc., a Delaware corporation, was founded in 1981. We are a biopharmaceutical company focused on developing and…View ↗
AMAG Pharmaceuticals, Inc., a Delaware corporation, was founded in 1981. We are a pharmaceutical company focused on bringing innovative…View ↗
Competes with American Regent, Fresenius Medical Care North America, Teva Pharmaceuticals, Allergan, Sanofi-Aventis U.S., Akebia Therapeutics, and Pharmacosmos
10-K for FY2019, filed Mar 6, 2020Injectafer®, a ferric carboxymaltose injection, which is approved to treat IDA in adult patients who have intolerance to oral iron or have…View ↗
Loading...
